Pooled Oncological Outcomes in Marjolin’s Ulcer: A Systematic Review and Meta-Analysis

Text
A recent systematic review and meta-analysis published in Cureus examines pooled oncological outcomes in patients with Marjolin’s ulcer, a rare and aggressive form of squamous cell carcinoma that develops in chronic wounds. The study, conducted by a team of dermatologists and oncologists, analyzed data from 23 peer-reviewed studies spanning 15 years to evaluate recurrence rates, metastasis risks, and survival outcomes among affected individuals.

Subheading
Methodology and Key Findings
The research team performed a comprehensive search of medical databases, including PubMed, Scopus, and the Cochrane Library, to identify studies on Marjolin’s ulcer published between 2009 and 2024. After applying strict inclusion criteria, they pooled data from 1,245 patients across 23 studies. The analysis revealed that the pooled recurrence rate after initial treatment was 28.7% (95% CI, 24.3–33.4%), with metastasis occurring in 15.2% of cases (95% CI, 11.8–19.1%). Five-year overall survival rates averaged 58.3% (95% CI, 52.1–64.5%), while disease-free survival stood at 44.6% (95% CI, 38.9–50.6%).

The study also identified factors associated with poorer outcomes, including delayed diagnosis, larger tumor size at presentation, and incomplete surgical resection. Patients with tumors exceeding 2 cm in diameter had a 3.2-fold higher risk of metastasis compared to those with smaller lesions (OR 3.2, 95% CI 2.1–4.8). Additionally, the review found that adjuvant therapies such as radiotherapy and chemotherapy improved survival rates by 12–15% in patients with high-risk features.

Subheading
Clinical Implications and Limitations
The findings underscore the importance of early detection and aggressive treatment for Marjolin’s ulcer, a condition often linked to long-standing ulcers, burns, or chronic infections. "Marjolin’s ulcer is frequently misdiagnosed due to its similarity to benign wound complications," said Dr. Emily Torres, a co-author of the study and a dermatologist at the University of California, San Francisco. "Our analysis highlights the need for heightened vigilance in patients with chronic wounds, particularly those over 50 years old or with a history of radiation exposure."

However, the study’s authors acknowledged several limitations. The pooled data included heterogeneous patient populations and treatment protocols, which may affect the generalizability of the results. Additionally, many of the included studies were retrospective, increasing the risk of bias. The researchers called for larger, prospective trials to validate their findings and refine treatment guidelines.

Subheading
Context Within Oncological Research
Marjolin’s ulcer is classified as a "cancer of chronic inflammation," with its development often tied to persistent tissue damage. The condition is relatively rare, with an estimated incidence of 0.1–0.3 per 100,000 people annually. Despite its low prevalence, the cancer’s aggressive nature and high recurrence rates make it a significant clinical challenge.

The Cureus study aligns with broader efforts to standardize care for rare cancers. In 2023, the National Cancer Institute updated its guidelines for managing squamous cell carcinomas, emphasizing multidisciplinary approaches and personalized treatment plans. The new analysis provides critical data to inform these recommendations, particularly regarding the role of adjuvant therapies in high-risk cases.

Subheading
Next Steps and Research Directions
The study’s authors emphasized that while their findings offer a clearer understanding of Marjolin’s ulcer outcomes, further research is needed to identify biomarkers for early detection and predict treatment responses. "We’re hoping to collaborate with genomic researchers to explore whether specific genetic mutations correlate with recurrence or metastasis," said Dr. Torres.

Healthcare providers are advised to remain cautious when managing chronic wounds, especially in high-risk populations. The study also highlights the value of interdisciplinary care, combining dermatology, oncology, and surgical expertise to improve patient outcomes.

Quoted text
"Marjolin’s ulcer is a silent but dangerous condition," said Dr. Torres. "Our analysis provides a data-driven framework to guide treatment decisions and improve survival rates."Source
Cureus, "Pooled Oncological Outcomes in Marjolin’s Ulcer: A Systematic Review and Meta-Analysis," July 2026.